The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy IndividualsNCT07252362
LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
A study testing American Gginseng in people with The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals, run by Zhejiang Cancer Hospital at 1 site in China.
Trial summary
Researchers will use LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine and Plasma in Healthy Individuals Participants will: Take 3 grams of American Ginseng powder every day for 14 days Collect the fasting urine samples at the following times at the hospital: On the first day, on the 7th day… Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals
- What is being tested?
- American Gginseng
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 11 Nov 2023to 30 Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
- 18 to 45 years old;
- The subjects were fully informed about the research process and signed the informed consent form (the subjects had no abnormalities in routine physical examinations, no previous medical history, and no history of drug allergies); ③ During the trial, they were required to have a light diet and were prohibited from consuming alcoholic and caffeinated beverages;
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310000
guan ai Bao, Master, +8615968857341, doctorbga@126.com
About this study
Researchers will use LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
Participants will:
- Take 3 grams of American Ginseng powder every day for 14 days
- Collect the fasting urine samples at the following times at the hospital: On the first day, on the 7th day after taking the medicine, and on the 14th day after taking the medicine.
- Collect the fasting Serum samples at the following times at the hospital: On the first day and on the 14th day after taking the medicine.
- Have their any adverse effects monitored and evaluated throughout the study.
- Conditions
- The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals
- Being tested
- American Gginseng
- Keywords
- American ginseng, metabolomics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
American GginsengOther
All the subjects took 3 grams of ginseng half an hour after breakfast every day for 14 consecutive days.
| Study group | Role | What they receive |
|---|---|---|
| American Ginseng group | Other | All the subjects took 3 grams of American ginseng half an hour after breakfast every day for 14 consecutive days. Receives: Other: American Gginseng |
What is being measured
The primary outcome is the main question the study is designed to answer.
Urine metabolomics
By using LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine in Healthy Individuals
Measured: From enrollment to the end of treatment at 2 weeks
Secondary outcomes (1)
Plasma metabolomics
By using LCMS Metabolic Analysis to Explore the Effect of American Ginseng on plasma in Healthy Individuals.
Measured: From enrollment to the end of treatment at 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Nov 2025
- Study start11 Nov 2023
- Primary completion30 Dec 2025 (estimated)
- Study completion30 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy IndividualsStudies of the same condition, open and under way.
- More trials run by Zhejiang Cancer HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhejiang Cancer Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, baoguanai, Zhejiang Cancer Hospital
- Investigators
- guan ai Bao, Master, Study director, Zhejiang Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07252362
- Sponsor's protocol ID
- 2021KY577
- Status last verified
- Nov 2025
- First submitted
- 18 Nov 2025
- Last updated
- 26 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
- ClinicalTrials.gov ID
- NCT07252362
- Acronym / sponsor ID
- 2021KY577
- Conditions
- The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals
- Keywords
- American ginseng, metabolomics
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Zhejiang Cancer HospitalUniversity, hospital or other
- Study start
- 11 Nov 2023 (actual)
- Primary completion
- 30 Dec 2025 (estimated)
- Study completion
- 30 Mar 2026 (estimated)
- First posted
- 26 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Researchers will use LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
Participants will:
- Take 3 grams of American Ginseng powder every day for 14 days
- Collect the fasting urine samples at the following times at the hospital: On the first day, on the 7th day after taking the medicine, and on the 14th day after taking the medicine.
- Collect the fasting Serum samples at the following times at the hospital: On the first day and on the 14th day after taking the medicine.
- Have their any adverse effects monitored and evaluated throughout the study.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| American Ginseng group | Other | Other: American GginsengAll the subjects took 3 grams of American ginseng half an hour after breakfast every day for 14 consecutive days. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| American GginsengAll the subjects took 3 grams of ginseng half an hour after breakfast every day for 14 consecutive days. | Other | American Ginseng group |
Primary outcome
Urine metabolomics
Time frame: From enrollment to the end of treatment at 2 weeks
By using LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine in Healthy Individuals
1 secondary outcome
Plasma metabolomics
Time frame: From enrollment to the end of treatment at 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
guan ai Bao, Master study director
Zhejiang Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing American Gginseng in people with The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals, run by Zhejiang Cancer Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact guan ai Bao, Master (+8615968857341, doctorbga@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Urine metabolomics (time frame: From enrollment to the end of treatment at 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2025.